BioNTech sees up to EUR 17 B in Vaccine Revenue

Germany’s BioNTech SE said the COVID-19 vaccine it is developing with Pfizer will likely generate up to 17 billion euros ($19.6 billion) in revenues this year, as booster shots take hold and use in children increases.